Virtual screening for triple-negative breast cancer cell inhibitors based on telomere G-quadruplex structure

doi:10.5246/jcps.2020.06.036

Journal of Chinese Pharmaceutical Sciences ›› 2020, Vol. 29 ›› Issue (6): 383-389.DOI: 10.5246/jcps.2020.06.036

• Original articles • Previous Articles Next Articles

Virtual screening for triple-negative breast cancer cell inhibitors based on telomere G-quadruplex structure

Hua Deng⁺, Chao Gao⁺, Dengguo Wei^*, Sisi Liu^*

Department of Chemistry, College of Science, Huazhong Agricultural University, Wuhan 430070, China

Received:2019-12-30 Revised:2020-02-13 Online:2020-06-30 Published:2020-03-18
Contact: Tel.: +86-27-87282133, E-mail: dgwei@mail.hzau.edu.cn; liusisi@mail.hzau.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 31701791, 21732002, 31672558 and 21502060), Huazhong Agricultural University Scientific & Technological Self-innovation Foundation (Grant No. 2662017PY113, 2015RC013 and 2662015PY208), Open fund of The State Key Laboratory of Bio-organic and Natural Products Chemistry, CAS (Grant No. SKLBNPC16343).

Abstract

Abstract:

Triple-negative breast cancer is an aggressive subtype that frequently develops resistance to chemotherapy. It is expectedto develop new anti-tumor drugs through targeting the structure of G-quadruplexes of the genes associated with this tumor. In this work, by targeting the 21-mer telomere G-quadruplex structure, compounds VB07 and VC02 were identified to stabilize the telomere G-quadruplex through structure-based high-throughput virtual screening. Cell cytotoxicity assay showed that VB07 and VC02 exhibited inhibitory effect on triple-negative breast cancer cells at the concentration of 5 μM. This study showed that structure-based high-throughput virtual screening was able to successfully identify the proper compounds targeting the telomere G-quadruplex, which exhibited inhibitory effects against thetriple-negative breast cancer cells.

Key words: Triple-negative breast cancer, Telomere G-quadruplex, Structure-based virtual screening, Anti-cancer drug

CLC Number:

R966

Supporting:

Hua Deng, Chao Gao, Dengguo Wei, Sisi Liu. Virtual screening for triple-negative breast cancer cell inhibitors based on telomere G-quadruplex structure[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 383-389.

References

[1] Kim, C.; Gao, R.L.; Sei, E.; Brandt, R.; Hartman, J.; Hatschek, T.; Crosetto, N.; Foukakis, T.; Navin, N.E. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018, 173, 879-893.e13.

[2] Denkert, C.; Liedtke, C.; Tutt, A.; von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017, 389, 2430-2442.

[3] Xiong, Y.X.; Huang, Z.S.; Tan, J.H. Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives. Eur. J. Med. Chem. 2015, 97, 538-551.

[4] Zhou, J.M.; Zhu, X.F.; Lu, Y.J.; Deng, R.; Huang, Z.S.; Mei, Y.P.; Wang, Y.; Huang, W.L.; Liu, Z.C.; Gu, L.Q.; Zeng, Y.X. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene. 2006, 25, 503-511.

[5] Riou, J.F.; Guittat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitgenet, O.; Mégnin-Chanet, F.; Hélène, C.; Mergny, J.L. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA. 2002, 99, 2672-2677.

[6] Burger, A.M.; Dai, F.P.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65, 1489-1496.

[7] Che, T.; Chen, S.B.; Tu, J.L.; Wang, B.; Wang, Y.Q.; Zhang, Y.; Wang, J.; Wang, Z.Q.; Zhang, Z.P.; Ou, T.M.; Zhao, Y.; Tan, J.H.; Huang, Z.S. Discovery of novel schizocommunin derivatives as telomeric G-quadruplex ligands that trigger telomere dysfunction and the deoxyribonucleic acid (DNA) damage response. J. Med. Chem. 2018, 61, 3436-3453.

[8] Guo, L.X.; Yin, F.; Jing, J.J.; Liu, J.H. Triethylene tetramine, a novel ligand of G-quadruplex, induces senescence of MCF-7 cells. Biotechnol. Lett. 2008, 30, 47-53.

[9] Konieczna, N.; Romaniuk-Drapała, A.; Lisiak, N.; Totoń, E.; Paszel-Jaworska, A.; Kaczmarek, M.; Rubiś, B. Telomerase inhibitor TMPyP4 alters adhesion and migration of breast-cancer cells MCF7 and MDA-MB-231. Int. J. Mol. Sci. 2019, 20, E2670.

[10] Sun, D.; Thompson, B.; Cathers, B.E.; Salazar, M.; Kerwin, S.M.; Trent, J.O.; Jenkins, T.C.; Neidle, S.; Hurley, L.H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40, 2113-2116.

[11] Biffi, G.; Tannahill, D.; McCafferty, J.; Balasubramanian, S. Quantitative visualization of DNA G-quadruplex structures in human cells. Nat. Chem. 2013, 5, 182-186.

[12] Calado, R.T.; Young, N.S. Telomere diseases. N. Engl. J. Med. 2009, 361, 2353-2365.

[13] Balasubramanian, S.; Hurley, L.H.; Neidle, S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat. Rev. Drug Discov. 2011, 10, 261-275.

[14] Pattanayak, R.; Barua, A.; Das, A.; Chatterjee, T.; Pathak, A.; Choudhury, P.; Sen, S.; Saha, P.; Bhattacharyya, M. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. Eur. J. Pharm. Sci. 2018, 125, 39-53.

[15] Sissi, C.; Palumbo, M. Telomeric G-quadruplex architecture and interactions with potential drugs. Curr. Pharm. Des. 2014, 20, 6489-6509.

[16] Neidle, S. Quadruplex nucleic acids as novel therapeutic targets. J. Med. Chem. 2016, 59, 5987-6011.

[17] Lin, C.; Yang, D.Z. Human telomeric G-quadruplex structures and G-quadruplex-interactive compounds. Methods Mol. Biol. 2017, 1587, 171-196.

[18] Monsen, R.C.; Trent, J.O. G-quadruplex virtual drug screening: a review. Biochimie. 2018, 152, 134-148.

[19] Micco, M.; Collie, G.W.; Dale, A.G.; Ohnmacht, S.A.; Pazitna, I.; Gunaratnam, M.; Reszka, A.P.; Neidle, S. Structure-based design and evaluation of naphthalene diimide G-quadruplex ligands as telomere targeting agents in pancreatic cancer cells. J. Med. Chem. 2013, 56, 2959-2974.

[20] Zhai, Q.Q.; Gao, C.; Ding, J.Q.; Zhang, Y.S.; Islam, B.; Lan, W.X.; Hou, H.T.; Deng, H.; Li, J.; Hu, Z.; Mohamed, H.I.; Xu, S.Z.; Cao, C.Y.; Haider, S.M.; Wei, D.G. Selective recognition of c-MYC Pu22 G-quadruplex by a fluorescent probe. Nucleic Acids Res. 2019, 47, 2190-2204.

Virtual screening for triple-negative breast cancer cell inhibitors based on telomere G-quadruplex structure

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	Wentao Zhu, Wanglong Hong, Miaomiao Zheng, Guoqiang Ma, Aizong Shen. Combination of pembrolizumab and chemotherapy as first-line treatment in advanced triple-negative breast cancer: a cost-effectiveness analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 587-597.
[2]	Haitao Hou, Zibing Song, Jieqin Ding, Dengguo Wei, Sheng Hu, Qianqian Zhai, Xiali Yue. Berberine enhances the activity of Sunitinib by targeting telomere G-quadruplex [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 289-297.
[3]	Yao Zhao, Jingying Zhang, Yingjie Hu, Jiashuan Wu, Yingzi Bu, Wanliang Lu. Augmented efficacy and the mechanism of a combined use of daunorubicin with rofecoxib in treatment of triple-negative breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(6): 438-447.